{"transactions":[{"id":691598,"issuer":{"id":4564,"kind":"organization","name":"Braveheart Bio, Inc."},"owners":[{"id":24906,"kind":"organization","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","position":1,"cik":"0002080343","reported_name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Non-voting Series A preferred stock","published_at":"2026-08-10T14:03:28.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":false,"shares":32500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The non-voting Series A preferred stock (the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The non-voting Series A preferred stock (the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The non-voting Series A preferred stock (the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7420091},"source":{"system":"sec-edgar","filing":"0001104659-26-093140","document":"tm2622685-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2080343/000110465926093140/tm2622685-1_4seq1.xml","form_type":"4"}},{"id":691597,"issuer":{"id":4564,"kind":"organization","name":"Braveheart Bio, Inc."},"owners":[{"id":24906,"kind":"organization","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","position":1,"cik":"0002080343","reported_name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T14:03:28.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":true,"shares":7420091,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The non-voting Series A preferred stock (the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."}],"balance_after":7420091,"source":{"system":"sec-edgar","filing":"0001104659-26-093140","document":"tm2622685-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2080343/000110465926093140/tm2622685-1_4seq1.xml","form_type":"4"}},{"id":802313,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":24906,"kind":"organization","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","position":1,"cik":"0002080343","reported_name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 convertible non-voting preferred stock","published_at":"2026-04-22T10:03:23.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":708814,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2034133},"source":{"system":"sec-edgar","filing":"0001104659-26-046276","document":"tm2612225-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2096997/000110465926046276/tm2612225-1_4seq1.xml","form_type":"4"}},{"id":802312,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":24906,"kind":"organization","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","position":1,"cik":"0002080343","reported_name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 convertible preferred stock","published_at":"2026-04-22T10:03:23.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":4968789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9477719},"source":{"system":"sec-edgar","filing":"0001104659-26-046276","document":"tm2612225-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2096997/000110465926046276/tm2612225-1_4seq1.xml","form_type":"4"}},{"id":802311,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":24906,"kind":"organization","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","position":1,"cik":"0002080343","reported_name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T10:03:23.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":2034133,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."}],"balance_after":2034133,"source":{"system":"sec-edgar","filing":"0001104659-26-046276","document":"tm2612225-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2096997/000110465926046276/tm2612225-1_4seq1.xml","form_type":"4"}},{"id":802310,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":24906,"kind":"organization","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","position":1,"cik":"0002080343","reported_name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T10:03:23.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":9477719,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."}],"balance_after":9477719,"source":{"system":"sec-edgar","filing":"0001104659-26-046276","document":"tm2612225-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2096997/000110465926046276/tm2612225-1_4seq1.xml","form_type":"4"}}]}